Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Expert video report on Urothelial Carcinoma from 2021 Genitourinary Cancers Symposium

Reporting from the 2021 Genitourinary Cancers Symposium, Matthew Galsky features practice changing results from Urothelial Carcinoma studies testing adjuvant nivolumab after radical surgery in muscle-invasive disease with high risk for relapse, and evaluating enfortumab vedotin vs standard chemotherapy in patients with previously treated advanced disease.

Abstracts:

  • Abstract 391: First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC), Dean Bajorin
  • Abstract 393: Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma, Thomas Powles

This video was supported with an educational grant from Janssen Oncology

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings